Epiontis GmbH

Epiontis GmbH specializes in immune monitoring services, utilizing proprietary epigenetic technology to analyze immune cells. Their services support pharmaceutical and life sciences sectors, focusing on enhancing clinical research outcomes. Founded in 2003, Epiontis GmbH is based in Berlin, Germany. The company focuses on immune monitoring services and has undergone a strategic acquisition by Precision for Medicine, Inc.

in October 2017. Over the years, Epiontis has successfully completed 2 deals, with its latest significant funding round being a Seed round of EUR 0. 800 mn, led by investors such as Epigenomics AG and the German Federal Ministry for Economic Affairs and Climate Action. The total amount raised by the company to date is EUR 0.

800 mn. Epiontis ID® offers a variety of immune monitoring services, leveraging advanced epigenetic technology to profile immune cells through DNA methylation analysis. With over 35 validated assays, the company provides analysis for various sample types including whole blood, PBMCs, and FFPE tissues. Epiontis ID® supports clients globally, particularly in North America, Europe, and Asia-Pacific, assisting pharmaceutical and life sciences organizations in clinical research, especially in oncology and autoimmune diseases.

In 2022, Epiontis GmbH reported a revenue of EUR 12,822,952. 70 and an EBITDA of EUR 1,207,420. 80. The company generates revenue primarily through B2B transactions, providing customized assay services tailored to the specific needs of its clients in the pharmaceutical and life sciences sectors.

Epiontis GmbH aims to expand its service offerings by developing new products that enhance immune monitoring capabilities. The company is also targeting expansion into additional markets, focusing on North America and Asia-Pacific to boost its global presence by 2024. The recent funding from their Seed round will be utilized to support these initiatives and enhance product development, ensuring that they meet the evolving needs of clinical research.